Xanamem Alzheimer’s Trial Misses Main Goal, Actinogen Shares Plunge Over 80%
Actinogen’s oral Xanamem missed its CDR-SB primary endpoint in the 247-patient XanaMIA Alzheimer’s trial. We explain the over-75 subgroup signal, the share collapse and what comes next.
